Fig. 5: The impact of sequential mass spectrometry on PFS and the combination with the cytogenetic risk status. | Blood Cancer Journal

Fig. 5: The impact of sequential mass spectrometry on PFS and the combination with the cytogenetic risk status.

From: Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Fig. 5: The impact of sequential mass spectrometry on PFS and the combination with the cytogenetic risk status.The alternative text for this image may have been generated using AI.

A PFS landmark analysis from 1 year (±3 months) of maintenance/observation. Patients were grouped according to the combination of the two mass spectrometry (MS) test results at the start of maintenance treatment/observation and after 1 year (±3 months) of maintenance treatment/observation. Four groups were discriminated against: sustained negativity (both MS tests negative), sustained positivity (both MS tests positive) as well as conversion from positivity to negativity (MS test positive -> negative) or vice versa (MS test negative -> positive). In (B) and (C) sustained MS negative and positive patients were further stratified by the baseline FISH risk status, respectively. High-risk cytogenetics were defined by the presence of t(4;14), t(14;16), del(17p) and/or gain(1q21).

Back to article page